Eli Lilly

Aging And Obesity Trends Will Expand Global Chronic Markets

AnalystHighTarget

Not Invested

Consensus Narrative from 26 Analysts

Published

04 May 25

Updated

15 Aug 25

AnalystHighTarget's Fair Value

US$1,166.34

40.2% undervalued

15 Aug

US$698.05

-24.3%

9.9%

Author's Valuation

US$1.2k

40.2% undervalued

AnalystHighTarget Fair Value

Narrative

Updates1

Shared on07 May 25
Fair value Decreased 1.99%

AnalystHighTarget Fair Value

US$1.2k

40.2% undervalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

13.98%

Pharma revenue growth rate

0.57%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.78%

Calculation

US$39.70b

Earnings '28

31.80x

PE Ratio '28

US$1.26t

Market Cap '28

US$1.26t

Market Cap '28

889.71m

No. shares '28

US$1.42k

Share Price '28

US$1.42k Share Price '28

Discounted to 2025 @ 6.78% p.a.

US$1.17k

Fair Value '25

Aging And Obesity Trends Will Expand Global Chronic Markets

Shared on07 May 25Fair value Decreased 1.99%

Shared on07 May 25
Fair value Decreased 1.99%